CRISPR and Acute Myeloid Leukemia (AML)

AvenCell Therapeutics recently announced that the first patient has been dosed in a Phase 1A study with its lead product candidate AVC-201. This novel...

Clinical Highlights From the Gene-Editing Field in...

CMN Clinical

Dec. 29, 2023

As 2023 draws to a close, we look back on some of the major clinical highlights from the year gone by.

Recent Clinical Updates From the Gene-Editing...

Nov. 22, 2023

In this article, we look at recent clinical updates from the gene-editing field. These updates include clinical data from Vor Bio's ongoing Phase 1/2a...

CRISPR Helps Decode the Epigenetic Mysteries of...

Sep. 25, 2023

Leading epigeneticist Gabriella Ficz has used CRISPR technology to investigate the interplay between DNA methylation and cancer. Her latest findings...

Clinical Trial Update: Beam Therapeutics Doses...

Sep. 6, 2023

Beam Therapeutics reports dosing of the first patient with BEAM-201, a multiplex-edited allogeneic CAR-T cell candidate developed to treat relapsed or...

European Clinical Trial Approved for First...

Aug. 9, 2023

AvenCell Therapeutics announces that the European Medicines Agency has approved its clinical trial application for AVC-201, a novel CRISPR-edited and...

Clinical Roundup: Gene-Edited CAR T Therapies

Feb. 6, 2023

In recent years, researchers have turned to gene editing to address the limitations of CAR T therapies. This roundup summarises the clinical-stage...

Clinical update: FDA Upgrades Status for Two...

Mar. 16, 2022

This week's update includes news about two gene-edited therapies for cancer. Allogene Therapeutics' ALLO-316 has been granted Fast Track Designation...